期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地西他滨治疗骨髓增生异常综合征的观察护理 被引量：8

暂未订购
导出
摘要 目的:观察地西他滨治疗骨髓增生异常综合征的不良反应及护理效果。方法:观察7例应用地西他滨治疗的骨髓增生异常综合征病人的用药准备、用药情况、不良反应及护理结果。结果:地西他滨治疗的不良反应有血小板减少、中性粒细胞减少、贫血、感染、胃肠道反应、肝功能损害、皮疹、口腔溃疡等。经采取有效的护理措施及对症支持治疗,症状大都减轻或者好转。结论:对病人进行针对性护理,可以有效减轻用药不良反应,有利于病人更好地配合治疗。
作者 方颖 孙彩虹 鲁玲玲 赵小萍
机构地区 浙江大学医学院附属第一医院血液病科
出处 《护理实践与研究》 2012年第11期60-61,共2页 Nursing Practice and Research
关键词 地西他滨 骨髓增生异常综合征 护理
分类号 R473.5 [医药卫生—护理学]
  • 相关文献

参考文献6

  • 1谭昀杜熙,杨薇,李玉珍.治疗骨髓增生异常综合征新药——地西他滨[J].中国新药杂志,2010,19(2):91-94. 被引量：4
  • 2高冲,陈宝安,刘苒,徐昕,丁家华,王骏,程坚,赵刚,余正平,宋慧慧,鲍文.地西他滨治疗骨髓增生异常综合征一例报告[J].现代医学,2010,38(2):189-190. 被引量：10
  • 3Zagonel V. 5 -aza-2-decitabine induces trilineage response in unfavourable myelodysplastic syndromes [ J ]. Leukemia, 1993,7 (11) :30-35.
  • 4Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes results of a phase Ⅲ randomized study [J]. Cancer, 2006,106 ( 8 ) : 1794-1803.
  • 5Wij ermans PW, Lubbert M, Verhoff G, et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5 aza-2-decitabine in 177 patients [ J ]. Ann Hemato1,2005,84 ( Suppl 13 ) :9-17.
  • 6Wijermans P,Lubbert M, Verhoff G, et al. Lowdose 5-Aza-2 deoxycytidine, a DNA hpyomethylating agent, for the treatment of highrisk myelodysplastic syndrome:A multicenter phase Ⅱ study in elderly patients[J]. J Clin Oncol,2000,18(5) :956-962.

二级参考文献14

  • 1夏瑞祥,蔡学杰.地西他滨在恶性血液病中的作用[J].安徽医药,2006,10(12):900-901. 被引量：4
  • 2杨薇,陈银海,崔恒宓.地西他滨和5-阿扎胞苷在癌症研究及临床上的应用[J].中国药学杂志,2006,41(21):1601-1605. 被引量：5
  • 3陈娜,董金华.地西他滨(decitabine)[J].中国药物化学杂志,2007,17(3):196-196. 被引量：1
  • 4CASHEN A,SHAH A, HELGET A,et al. A phase Ⅰ pharmacokinetie trial of decitabine administered as a 3-hour infusion to patientswith acute myelogenous leukemia(AML) or myelodysp lastic syndrome (MDS) [ J ]. Blood ( ASH Annual Meeting Abstracts), 2005,106 : Abstract 1854.
  • 5LUBBERT M, DASKALAKIS M, KUNZMANN R ,et al. Nonelonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine(decitabine) [ J ]. Leuk Res, 2004,28(12) :1267 - 1271.
  • 6KANTARJIAN H, ISSA JP, ROSENFELD CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase Ⅲ randomized study [ J ]. Cancer, 2006, 106 ( 8 ) : 1794 - 1803.
  • 7RUTER B, WIJERMANS PW, LUBBERT M. Results of 5-aza-2'- deoxycytidine retreatment in high-risk myelodysplasia patients [ J ]. Cancer,2006,106 ( 8 ) : 1744 - 1750.
  • 8STONE MR. Are new agents really making a difference in MDS? [ J ]. Res Clin Haematol, 2008,21 (4) :639 - 646.
  • 9WIJERMANS P,LUBBERT M,VERHOEF G,et al.Low-dose5-Aza-2'-deoxycytidine,a DNA hypomethylating agent,for the treatment of high-risk myelodysplastic syndrome:A multicenter phase Ⅱ study in elderly patients.Ann Hematol,2005,84(Suppl 13):9-17.
  • 10WIJERMANS P W,LUBBERT M,VERHOEF G,et al.An epigenetic approach to the treatment of advanced MDS;the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine(decitabine) in 177 patients[J].Ann Hematol,2005,84(Suppl 13):9-17.

共引文献11

同被引文献61

  • 1Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high- risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy : final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol, 2011:29 ( 15 ) _. 1987 - 1996.
  • 2张之南,沈悌.血液学诊断及疗效标准.第3版,北京,科学出版社,2006.279-281.
  • 3Saba HI. Decitabine in the treatment of myelodysplastic syn- dromes. Ther Clin Risk Manag, 2007 ;3 (5) : 807 -817.
  • 4Qin T, Castoro R, E1 AS, et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One, 2011 ; 6 (8) : 23372 -23382.
  • 5Steensma DP, Baer MR, Slack JL, et al. Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treaanent (ADOPT) trial. J Clin Oncol, 2009 ; 27 ( 23 ) : 3842 - 3848.
  • 6Borthakur G, Ahdab SE, Ravandi F, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma,2008 ;49(4) : 690 - 695.
  • 7Santos FP, Kantarjian H, Garcia-Manero G, et al. Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther, 2010;10(1) : 9 -22.
  • 8Lee JH, Lee KH, Lee JH, et al. Decreased incidence of febrile episodes with antibiotic prophylaxis in the treatment of decitabine for myelodysplastic syndrome. Leuk Res, 2011 ; 35 (4) : 499 - 503.
  • 9Guo M, Hu KX, Yu CL, et al. Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients. Blood, 2011;117 (3) : 936 -941.
  • 10Lubbert M,Suciu S,Baila L. Low-dose decitabine versus best supportive care in elderly patients with intermediate or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy:final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group[J].Clinical Oncology,2011,(15):1987-1996.

引证文献8

二级引证文献57

护理实践与研究
2012年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部